Europe built a test track for cancer AI. Now comes the hard part.

A radiologist sits with a stack of chest CTs. An AI tool flags one for "possible malignancy" and underlines a nodule the radiologist had not yet looked at. The radiologist re-reads the slice, agrees with the flag, and moves on. The question most hospital IT departments still cannot answer is who tested the flagger, on what data, and against what ground truth before it was installed in the reading room.

That gap between a cancer AI demo in a paper and a cancer AI tool working on real patients is what the European CHAIMELEON consortium has spent the last few years trying to close. The consortium calls the gap the "AI chasm," and it is the right word: most oncology AI tools reach the clinic through small, single-site, vendor-run studies that do not test the algorithm on the multi-institution, multi-vendor scanner mess that real radiology departments actually run. CHAIMELEON is a web-based platform where radiologists can grade cancer imaging algorithms on standardized data before hospitals deploy them, rather than trusting only the vendor's published study. The [methods paper, published in European Radiology Experimental](https://pubmed.ncbi.nlm.nih.gov/42536277/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1pq-4TZ0w1pFimBiBDzqh3Xb91p8c5aLdm8-icUqTMkiVoUsnC&fc=20260714194710&ff=20260731162925&v=2.20.0.post5+40e1b98), describes the architecture: containerized microservices running on Kubernetes, an ORTHANC-based PACS for imaging, Keycloak and OAuth2 for security, and a customized OHIF DICOM viewer so reviewers can read studies through a browser. It is one of the work packages inside the broader EU CORDIS project 952172, titled "Accelerating the lab to market transition of AI tools for cancer management," and is being built to plug into the wider EUCAIM pan-European cancer imaging infrastructure.

The workflow the consortium put clinicians through is the part that matters most. Each reviewer did three things: a standard clinical read of the case, a second read with the AI's prediction shown alongside the images, and a final review against a clinical-endpoint ground truth, a known biopsy result or follow-up diagnosis, not the AI's call. After the cases, reviewers filled out a Likert-scale questionnaire on whether the AI was useful, whether they trusted it, whether it fit their workflow, and whether they would recommend the platform. Across five cancer types, 93% of the clinicians rated the platform as intuitive and more than 80% said they would recommend it; agreement that the AI was useful cleared 40% on most endpoints. The design intent, repeated in the paper, is that the AI is a "second reader" that prompts a re-look, not a system that tries to override the radiologist.

Those are usability and acceptance numbers, not clinical efficacy numbers, and the gap between the two is the story's center of gravity. A platform that clinicians find intuitive and would recommend is necessary infrastructure. It is not, by itself, evidence that any specific cancer AI is ready to change a patient's care. The 93% / 80% / 40% figures measure how the test bench is received, not how the tools running on it perform against the disease. CHAIMELEON's authors frame the platform as a foundation for that next step. The platform is modular, designed to ingest additional AI models, and intended to interoperate with the EU's Cancer Image Europe platform, whose first prototype went live in the same news cycle. The study is registered on ClinicalTrials.gov as NCT06950996 and the CHAIMELEON project site and its open challenges on Grand Challenge lay out the next rounds of evaluation.

The Commission's broader play runs through EUCAIM, its attempt to pool cancer imaging data and AI validation across member states. Cancer Image Europe is the public-facing half of that push. A radiologist in Lisbon, a regulatory reviewer in Brussels, and a vendor pitching to a hospital in Milan would, in theory, all be looking at the same benchmark, the same ground truth, and the same clinician-rated usability score. If the framework holds, a cancer AI tool's clinical case would no longer rest on the study its own manufacturer chose to run.

The next round of CHAIMELEON challenges is open on Grand Challenge, and the consortium's roadmap treats the platform as a foundation for additional model integrations. The next test is whether a tool that has cleared CHAIMELEON does better in a real radiology department than one that has not. Until that comparison is run, the platform is a credible attempt at the plumbing, and a credible test bench is the precondition for the rest.